Inspira Selects GlobalLogic to Develop Platform for respiratory failure device

GlobalLogic will develop the algorithm-enhanced digital platform powering the ART device – a respiratory support system being developed by Inspira

GlobalLogic, a Hitachi Group Company and digital engineering specialist, has been selected by Inspira Technologies to develop an algorithm-enhanced platform powering the ART device—an Early Extracorporeal Respiratory Support system targeting respiratory failure patients such as those diagnosed with COVID-19.

Inspira Technologies created the ART, a novel low-flow early extracorporeal approach to address the patient population whose condition continues to deteriorate following non-invasive ventilation. As of today, the only treatment available for them after non-invasive ventilation is the highly invasive mechanical ventilation. The ART device utilises a haemo-protective flow approach designed to rebalance oxygen saturation levels while patients are awake and breathing spontaneously, potentially minimising the need for mechanical ventilation. The ART is designed to enrich ~200cc of blood at any given point, elevating the oxygen saturation levels in one minute.


To read this news in details, please visit:

  • URL copied!